Chiara Zecca1, Letizia Panicari1, Giulio Disanto1, Paolo Maino2, Anand Singh3,4, G Alessandro Digesu5,6,7,8, Claudio Gobbi1. 1. Department of Neurology, Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, Lugano, Switzerland. 2. Anestesiologia, Ospedale Regionale di Lugano, Lugano, Switzerland. 3. St. Mary's Hospital, Imperial College School of Medicine, London, UK. 4. National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom. 5. St. Mary's Hospital, Imperial College School of Medicine, London, UK. a.digesu@imperial.ac.uk. 6. National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom. a.digesu@imperial.ac.uk. 7. Urogynaecology Unit, Ospedale Regionale di Mendrisio, Mendrisio, Switzerland. a.digesu@imperial.ac.uk. 8. Department of Urogynaecology, S. Mary's Hospital, Academic Department of Obstetrics and Gynaecology, Mint Wing, South Wharf, W2 1NY, London, UK. a.digesu@imperial.ac.uk.
Abstract
INTRODUCTION AND HYPOTHESIS: Bladder dysfunction is a frequent symptom complex in patients with multiple sclerosis (MS) and often compromises the patient's quality of life. Pharmacotherapy has been poorly studied in the MS population showing contradictory results and reduced compliance owing to intolerable side effects. A new neuromodulation technique known as percutaneous tibial nerve stimulation (PTNS) has shown good efficacy and safety in the treatment of neurogenic and non-neurogenic lower urinary tract symptoms. In this article we review the literature and critically summarise the scientific evidence supporting the use of PTNS in the treatment of lower urinary tract symptoms (LUTS) in patients with MS. METHODS: We performed a computer-aided literature search in PubMed and EMBASE up to January 2015 to identify randomised controlled trials, case-control trials and prospective observational cohort studies. RESULTS: A total of 7 open-label, prospective studies and 313 MS patients were included. Three studies reported clinical and urodynamic outcomes at 3 to 9 months after PTNS; one study assessed the long-term efficacy of PTNS; two studies reported the acute effect of PTNS on urodynamic findings; one study assessed whether motor and sensory responses during PTNS could predict treatment outcome. None of the studies included a control group. CONCLUSIONS: Despite the very limited data PTNS seems an effective and safe treatment option in the management of LUTS in patients with MS.
INTRODUCTION AND HYPOTHESIS: Bladder dysfunction is a frequent symptom complex in patients with multiple sclerosis (MS) and often compromises the patient's quality of life. Pharmacotherapy has been poorly studied in the MS population showing contradictory results and reduced compliance owing to intolerable side effects. A new neuromodulation technique known as percutaneous tibial nerve stimulation (PTNS) has shown good efficacy and safety in the treatment of neurogenic and non-neurogenic lower urinary tract symptoms. In this article we review the literature and critically summarise the scientific evidence supporting the use of PTNS in the treatment of lower urinary tract symptoms (LUTS) in patients with MS. METHODS: We performed a computer-aided literature search in PubMed and EMBASE up to January 2015 to identify randomised controlled trials, case-control trials and prospective observational cohort studies. RESULTS: A total of 7 open-label, prospective studies and 313 MS patients were included. Three studies reported clinical and urodynamic outcomes at 3 to 9 months after PTNS; one study assessed the long-term efficacy of PTNS; two studies reported the acute effect of PTNS on urodynamic findings; one study assessed whether motor and sensory responses during PTNS could predict treatment outcome. None of the studies included a control group. CONCLUSIONS: Despite the very limited data PTNS seems an effective and safe treatment option in the management of LUTS in patients with MS.
Authors: Vera Vandoninck; Michael R Van Balken; E Finazzi Agró; Filomena Petta; Carlo Caltagirone; John P F A Heesakkers; Lambertus A L M Kiemeney; Frans M J Debruyne; Bart L H Bemelmans Journal: Neurourol Urodyn Date: 2003 Impact factor: 2.696
Authors: M Queralto; G Portier; P H Cabarrot; G Bonnaud; J P Chotard; M Nadrigny; F Lazorthes Journal: Int J Colorectal Dis Date: 2005-12-06 Impact factor: 2.571
Authors: Morten V Fjorback; Farida S van Rey; Floor van der Pal; Nico J M Rijkhoff; Thor Petersen; John P Heesakkers Journal: Eur Urol Date: 2006-08-07 Impact factor: 20.096
Authors: Katarina Ivana Tudor; Jai H Seth; Martina D Liechti; Juliana Ochulor; Gwen Gonzales; Collette Haslam; Zoe Fox; Mahreen Pakzad; Jalesh N Panicker Journal: Clin Auton Res Date: 2018-08-03 Impact factor: 4.435